文献速递神经核医学肿瘤 PET/CT

Lafora病的FDG-PET评估与代谢模式

FDG-PET assessment and metabolic patterns in Lafora disease.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-12-19

该回顾性研究纳入8例经基因确诊的Lafora病(LD)患者,均在发病后平均6年行FDG-PET,视觉与SPM12分析显示全部患者存在双侧代谢减低区,以颞叶、顶叶、额叶及丘脑最常受累,3例复查显示代谢恶化。系统综述另纳入9例,FDG-PET表现异质。

要点

  • LD患者FDG-PET常见双侧颞叶、顶叶、额叶及丘脑代谢减低。
  • FDG-PET对LD各阶段均高度敏感,代谢减低范围随病情进展更弥漫。
  • 有视觉症状者较无视觉症状者颞顶叶代谢减低更显著。

核心结论

  • FDG-PET对评估Lafora病各阶段高度敏感,代谢减低区广泛累及皮层与皮层下,丘脑、颞叶、额叶和顶叶最严重。

研究设计与样本

  • 回顾性纳入3家意大利癫痫中心经基因确诊的Lafora病患者8例(3男/5女,3例EPM2A/5例NHLRC1),发病后平均6年(范围1-12年)行FDG-PET。
  • FDG-PET图像采用视觉评估和SPM12软件分析,并按遗传和临床特征进行SPM亚组分析。
  • 同时系统综述了8篇文献中9例接受FDG-PET评估的Lafora病病例。

主要发现

  • 全部8例患者显示双侧代谢减低区,晚期患者更弥漫和显著。
  • 代谢减低最常累及颞叶(8/8)、顶叶(7/8)、额叶(7/8)及丘脑(6/8)。
  • 3例在平均17个月(范围7-36个月)后复查FDG-PET,显示代谢较基线恶化。
  • SPM亚组分析未发现基于遗传学的显著差异,但有视觉症状者较无视觉症状者颞顶叶代谢减低更显著。
  • 系统综述的9例中FDG-PET表现异质,从弥漫性葡萄糖代谢减低到2例无异常。

关键数值与推荐

  • FDG-PET代谢减低区域:颞叶8/8、顶叶7/8、额叶7/8、丘脑6/8。
  • 复查FDG-PET间隔平均17个月(范围7-36个月)。
  • 有视觉症状者颞顶叶代谢减低较无视觉症状者更显著(SPM分析)。

临床怎么用

  • 对基因确诊的Lafora病患者,FDG-PET可用于评估脑代谢受累模式,各阶段均敏感。
  • 代谢减低范围广泛,读图时应关注颞叶、顶叶、额叶及丘脑等常见区域。
  • 有视觉症状的患者可重点关注颞顶叶代谢改变。

局限性

  • 回顾性设计,样本量小(8例意大利患者加文献9例)。
  • 复查FDG-PET仅3例,纵向数据有限。
  • 系统综述病例FDG-PET表现异质,需前瞻性纵向多中心研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe cerebral glucose metabolism pattern as assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in Lafora disease (LD), a rare, lethal form of progressive myoclonus epilepsy caused by biallelic mutations in EPM2A or NHLRC1. METHODS: We retrospectively included patients with genetically confirmed LD who underwent FDG-PET scan referred to three Italian epilepsy centers. FDG-PET images were evaluated both visually and using SPM12 software. Subgroup analysis was performed on the basis of genetic and clinical features employing SPM. Moreover, we performed a systematic literature review of LD cases that underwent FDG-PET assessment. RESULTS: Eight Italian patients (3M/5F, 3 EPM2A/5 NHLRC1) underwent FDG-PET examination after a mean of 6 years from disease onset (range 1-12 years). All patients showed bilateral hypometabolic areas, more diffuse and pronounced in advanced disease stages. Most frequently, the hypometabolic regions were the temporal (8/8), parietal (7/8), and frontal lobes (7/8), as well as the thalamus (6/8). In three cases, the FDG-PET repeated after a mean of 17 months (range 7-36 months) showed a metabolic worsening compared with the baseline examination. The SPM subgroup analysis found no significant differences based on genetics, whereas it showed a more significant temporoparietal hypometabolism in patients with visual symptoms compared with those without. In nine additional cases identified from eight publications, FDG-PET showed heterogeneous findings, ranging from diffusely decreased cerebral glucose metabolism to unremarkable examinations in two cases. CONCLUSIONS: FDG-PET seems highly sensitive to evaluate LD at any stage and may correlate with disease progression. Areas of decreased glucose metabolism in LD are extensive, often involving multiple cortical and subcortical regions, with thalamus, temporal, frontal, and parietal lobes being the most severely affected. Prospective longitudinal collaborative studies are needed to validate our findings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Muccioli L, Farolfi A, Pondrelli F, et al. FDG-PET assessment and metabolic patterns in Lafora disease. Eur J Nucl Med Mol Imaging. 2019. PMID: 31858178. doi:10.1007/s00259-019-04647-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。